News

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.4% year on year to $169.2 million. The company’s full-year revenue guidance of $707.5 million at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $0.39 per share was 11.4% above analysts’ consensus estimates.

Hillman (NASDAQ:HLMN) Misses Q1 Revenue Estimates

Hardware products and merchandising solutions provider Hillman (NASDAQ:HLMN) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 2.6% year on year to $359.3 million. On the other hand, the company’s full-year revenue guidance of $1.54 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $0.10 per share was in line with analysts’ consensus estimates.

Hillman (NASDAQ:HLMN) Misses Q1 Revenue Estimates

Hardware products and merchandising solutions provider Hillman (NASDAQ:HLMN) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 2.6% year on year to $359.3 million. On the other hand, the company’s full-year revenue guidance of $1.54 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $0.10 per share was in line with analysts’ consensus estimates.

NeoGenomics (NASDAQ:NEO) Misses Q1 Sales Targets, Stock Drops

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the company’s full-year revenue guidance of $753 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP loss of $0 per share was in line with analysts’ consensus estimates.

NeoGenomics (NASDAQ:NEO) Misses Q1 Sales Targets, Stock Drops

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the company’s full-year revenue guidance of $753 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP loss of $0 per share was in line with analysts’ consensus estimates.